Titan Pharmaceuticals upgraded by Maxim Group with a new price target
$TTNP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00
Save time and jump to the most important pieces.
Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00
Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy
Maxim Group upgraded Titan Pharmaceuticals from Hold to Buy and set a new price target of $11.00
NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ ("Blue Harbour"), it has completed a private placement of the Company's newly designated Series C Convertible Preferred Stock (the "Preferred Stock"). Pursuant to the Purchase Agreement, Blue Harbour purchased 60,000 shares of Preferred Stock for an aggregate purchase price of $600,000. The shares have a conversion price of $3.40. The Certificate of Designations authorizing the Preferred Stock contains a beneficial ownership conversion "blocke
NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission ("SEC") of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) ("TalenTec"), which includes Titan's preliminary proxy statement (the "Form F-4") As previously announced on August 19, 2024, Titan and TalenTec have entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business combination, pursuant to which Titan will be combined with TalenTec in a
NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ ("Blue Harbour"), it has completed a private placement of the Company's newly designated Series B Convertible Preferred Stock (the "Preferred Stock"). Pursuant to the Purchase Agreement, Blue Harbour purchased 100,000 shares of Preferred Stock for an aggregate purchase price of $1,000,000. The shares have a conversion price of $3.00. The Certificate of Designations authorizing the Preferred Stock contains a beneficial ownership conversion "bl
3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
3 - TITAN PHARMACEUTICALS INC (0000910267) (Issuer)
8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
8-K - TITAN PHARMACEUTICALS INC (0000910267) (Filer)
425 - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to
SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut
SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D/A - TITAN PHARMACEUTICALS INC (0000910267) (Subject)
SC 13D - TITAN PHARMACEUTICALS INC (0000910267) (Subject)